NASDAQ:NKTRNektar Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Nektar Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $24.38 -0.41 (-1.65 %) (As of 07/9/2020 01:14 PM ET) Add Compare Share Today's Range$24.10Now: $24.38▼$25.0650-Day Range$20.26MA: $22.38▼$24.1452-Week Range$13.63Now: $24.38▼$35.03Volume27,429 shsAverage Volume1.06 million shsMarket Capitalization$4.34 billionP/E RatioN/ADividend YieldN/ABeta2.01 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Nektar Therapeutics, a biopharmaceutical company, develops drug candidates for cancer, auto-immune disease, and chronic pain in the United States. The company develops NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; and NKTR-214, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in Phase I to treat immuno-oncology. It also develops NKTR-358, cytokine Treg stimulant, which is in Phase I to treat autoimmune diseases; NKTR-262, a toll-like receptor agonist that is in Phase I for solid tumors; and NKTR-255, which is in preclinical stage for immuno-oncology. In addition, the is developing ADYNOVATE and ADYNOVI for hemophilia A; MOVANTIK for opioid-induced constipation in adult patients with chronic non-cancer pain, and who have an inadequate response to laxatives; CIMZIA for crohn's disease, rheumatoid arthritis, and psoriasis/ankylosing spondylitis; and MIRCERA for anemia associated with chronic kidney disease. Further, it is developing Macugen for age-related macular degeneration; Somavert for acromegaly; Neulasta for neutropenia; Dapirolizumab Pegol for systemic lupus erythematosus; PEGPH20 for pancreatic, non-small cell lung cancer, and other tumor types; and longer-acting blood clotting proteins for hemophilia. The company has collaboration agreement with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Halozyme Therapeutics, Inc.; Bristol-Myers Squibb Company; Baxalta Incorporated; and Eli Lilly and Company, as well as with Merck KGaA and Pfizer Inc to develop a therapy for treating pancreatic cancer. Nektar Therapeutics was founded in 1990 and is headquartered in San Francisco, California.Read More Beat the Market (BTM) Rank™ 4.3 Analyst's Opinion Consensus RatingNektar Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 10 buy ratings, 7 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $32.00, Nektar Therapeutics has a potential upside of 31.3% from its current price of $24.38.Amount of Analyst CoverageNektar Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 3.0 Community Rank Outperform VotesNektar Therapeutics has received 617 “outperform” votes. (Add your “outperform” vote.)Underperform VotesNektar Therapeutics has received 402 “underperform” votes. (Add your “underperform” vote.)Community SentimentNektar Therapeutics has received 60.55% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Nektar Therapeutics and other stocks. Vote “Outperform” if you believe NKTR will outperform the S&P 500 over the long term. Vote “Underperform” if you believe NKTR will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldNektar Therapeutics does not currently pay a dividend.Dividend GrowthNektar Therapeutics does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Nektar Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $147,040.00 in company stock.Percentage Held by InsidersOnly 2.99% of the stock of Nektar Therapeutics is held by insiders.Percentage Held by Institutions98.20% of the stock of Nektar Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Nektar Therapeutics are expected to grow in the coming year, from ($2.55) to ($2.45) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Nektar Therapeutics is -9.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Nektar Therapeutics is -9.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNektar Therapeutics has a P/B Ratio of 3.05. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 4.3Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.78 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals SectorMedical Current SymbolNASDAQ:NKTR Previous Symbol CUSIP64026810 CIK906709 Webwww.nektar.com Phone415-482-5300Debt Debt-to-Equity Ratio0.11 Current Ratio3.79 Quick Ratio3.75Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$114.62 million Price / Sales37.86 Cash FlowN/A Price / Cash FlowN/A Book Value$7.99 per share Price / Book3.05Profitability EPS (Most Recent Fiscal Year)($2.52) Net Income$-440,670,000.00 Net Margins-335.50% Return on Equity-28.83% Return on Assets-20.58%Miscellaneous Employees618 Outstanding Shares177,990,000Market Cap$4.34 billion Next Earnings Date8/13/2020 (Estimated) OptionableOptionable NASDAQ:NKTR Rates by TradingView Receive NKTR News and Ratings via Email Sign-up to receive the latest news and ratings for NKTR and its competitors with MarketBeat's FREE daily newsletter. Nektar Therapeutics (NASDAQ:NKTR) Frequently Asked Questions How has Nektar Therapeutics' stock been impacted by COVID-19 (Coronavirus)? Nektar Therapeutics' stock was trading at $16.47 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, NKTR shares have increased by 48.0% and is now trading at $24.38. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Nektar Therapeutics? 18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nektar Therapeutics in the last year. There are currently 1 sell rating, 7 hold ratings and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Nektar Therapeutics. When is Nektar Therapeutics' next earnings date? Nektar Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Nektar Therapeutics. How were Nektar Therapeutics' earnings last quarter? Nektar Therapeutics (NASDAQ:NKTR) released its quarterly earnings results on Thursday, May, 7th. The biopharmaceutical company reported ($0.53) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.77) by $0.24. The biopharmaceutical company had revenue of $50.57 million for the quarter, compared to analysts' expectations of $46.88 million. Nektar Therapeutics had a negative net margin of 335.50% and a negative return on equity of 28.83%. Nektar Therapeutics's revenue for the quarter was up 79.2% on a year-over-year basis. During the same period last year, the firm posted ($0.68) earnings per share. View Nektar Therapeutics' earnings history. What price target have analysts set for NKTR? 18 brokers have issued 12 month price targets for Nektar Therapeutics' shares. Their forecasts range from $18.00 to $80.00. On average, they expect Nektar Therapeutics' stock price to reach $32.00 in the next twelve months. This suggests a possible upside of 31.3% from the stock's current price. View analysts' price targets for Nektar Therapeutics. What are Wall Street analysts saying about Nektar Therapeutics stock? Here are some recent quotes from research analysts about Nektar Therapeutics stock: 1. According to Zacks Investment Research, "Nektar reported encouraging fourth-quarter results, beating estimates for both earnings and sales. Nektar has a promising pipeline with several regulatory updates/data-readouts lined up for 2020. Moreover, regular partnerships have enhanced the company’s financial position. The blockbuster collaboration deal with Bristol-Myers for NKTR-214 significantly boosted Nektar’s cash resources. It also has encouraging co-development deals with other pharma companies. The deals boost revenues and reduce expenses by sharing research costs. On the flip side, Nektar relies heavily on partners for revenues. Partnership-related setbacks may thus weigh heavily on the company’s results in the future. Shares of the company have underperformed the industry in the past year." (4/15/2020) 2. HC Wainwright analysts commented, "Our new 12-month, $24, vs. our prior $47 target on shares of Nektar is based on a 12-year DCF-driven, sum-of-the-parts analysis. Our DCF is driven by beta of 1.62, terminal growth rate of 0.5%, risk premium of 4.93%, calculated WACC of 10.0%, and tax rate of 15% beginning in FY 2027." (8/13/2019) Has Nektar Therapeutics been receiving favorable news coverage? Media coverage about NKTR stock has trended negative this week, according to InfoTrie. InfoTrie rates the sentiment of press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Nektar Therapeutics earned a news impact score of -2.1 on InfoTrie's scale. They also assigned press coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View the latest news about Nektar Therapeutics. Who are some of Nektar Therapeutics' key competitors? Some companies that are related to Nektar Therapeutics include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Pfizer (PFE), Eli Lilly And Co (LLY), AbbVie (ABBV), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Royalty Pharma (RPRX), Horizon Therapeutics (HZNP), Mylan (MYL), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), Pacira Biosciences (PCRX), Corcept Therapeutics (CORT) and Zogenix (ZGNX). View all competitors. What other stocks do shareholders of Nektar Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Nektar Therapeutics investors own include NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), Gilead Sciences (GILD), Hawkins (HWKN), Incyte (INCY), Netflix (NFLX), Advanced Micro Devices (AMD), Intel (INTC) and Bristol-Myers Squibb (BMY). Who are Nektar Therapeutics' key executives? Nektar Therapeutics' management team includes the following people: Mr. Howard W. Robin, CEO, Pres & Director (Age 66)Mr. Gil M. Labrucherie, Sr. VP & CFO (Age 47)Mr. John Nicholson, Sr. VP & COO (Age 67)Dr. Maninder Hora, Sr. VP of Pharmaceutical Devel. & Chief Technical Operations Officer (Age 65)Dr. Stephen K. Doberstein, Chief R&D Officer (Age 60) What is Nektar Therapeutics' stock symbol? Nektar Therapeutics trades on the NASDAQ under the ticker symbol "NKTR." Who are Nektar Therapeutics' major shareholders? Nektar Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Private Asset Management Inc. (0.02%) and Mountain Capital Investment Advisors Inc (0.01%). Company insiders that own Nektar Therapeutics stock include Dennis L Winger, Gil M Labrucherie, Howard W Robin, Jeffrey Robert Ajer, Jillian B Thomsen, John Nicholson, Jonathan Zalevsky, Katharina Otto-Bernstein, Lutz Lingnau, Maninder Hora, R Scott Greer, Robert Chess and Stephen K Doberstein. View institutional ownership trends for Nektar Therapeutics. Which major investors are buying Nektar Therapeutics stock? NKTR stock was bought by a variety of institutional investors in the last quarter, including Private Asset Management Inc., and Mountain Capital Investment Advisors Inc. View insider buying and selling activity for Nektar Therapeutics. How do I buy shares of Nektar Therapeutics? Shares of NKTR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Nektar Therapeutics' stock price today? One share of NKTR stock can currently be purchased for approximately $24.38. How big of a company is Nektar Therapeutics? Nektar Therapeutics has a market capitalization of $4.34 billion and generates $114.62 million in revenue each year. The biopharmaceutical company earns $-440,670,000.00 in net income (profit) each year or ($2.52) on an earnings per share basis. Nektar Therapeutics employs 618 workers across the globe. What is Nektar Therapeutics' official website? The official website for Nektar Therapeutics is www.nektar.com. How can I contact Nektar Therapeutics? Nektar Therapeutics' mailing address is 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO CA, 94158. The biopharmaceutical company can be reached via phone at 415-482-5300 or via email at [email protected] This page was last updated on 7/9/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
